Corline Biomedical AB (CLBIO.ST)
SEK 9.48
(9.72%)
SEK 9.48
(9.72%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -17.01 Million SEK | 35.09% |
| 2022 | -26.21 Million SEK | 37.05% |
| 2021 | -41.63 Million SEK | -363.07% |
| 2020 | -8.99 Million SEK | 60.66% |
| 2019 | -22.85 Million SEK | 17.32% |
| 2018 | -27.64 Million SEK | -64.0% |
| 2017 | -16.85 Million SEK | -42.08% |
| 2016 | -11.86 Million SEK | -143.73% |
| 2015 | -4.86 Million SEK | -163.48% |
| 2014 | 7.66 Million SEK | 223.77% |
| 2013 | 2.36 Million SEK | 201.24% |
| 2012 | -2.33 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -12.76 Million SEK | 26.97% |
| 2024 Q1 | -17.47 Million SEK | -2.71% |
| 2023 Q1 | -19.84 Million SEK | 24.3% |
| 2023 Q3 | -17 Million SEK | 20.18% |
| 2023 Q4 | -17.01 Million SEK | -0.07% |
| 2023 FY | -17.01 Million SEK | 35.09% |
| 2023 Q2 | -21.29 Million SEK | -7.35% |
| 2022 Q1 | -35.58 Million SEK | 14.53% |
| 2022 Q4 | -26.21 Million SEK | 8.81% |
| 2022 Q3 | -28.74 Million SEK | 11.2% |
| 2022 FY | -26.21 Million SEK | 37.05% |
| 2022 Q2 | -32.36 Million SEK | 9.04% |
| 2021 FY | -41.63 Million SEK | -363.07% |
| 2021 Q3 | -42.93 Million SEK | 9.99% |
| 2021 Q4 | -41.63 Million SEK | 3.03% |
| 2021 Q1 | -19.42 Million SEK | -116.07% |
| 2021 Q2 | -47.7 Million SEK | -145.56% |
| 2020 Q1 | -16.87 Million SEK | 26.17% |
| 2020 FY | -8.99 Million SEK | 60.66% |
| 2020 Q3 | -7.84 Million SEK | 36.92% |
| 2020 Q4 | -8.99 Million SEK | -14.58% |
| 2020 Q2 | -12.43 Million SEK | 26.29% |
| 2019 Q2 | -32.89 Million SEK | -44.3% |
| 2019 FY | -22.85 Million SEK | 17.32% |
| 2019 Q4 | -22.85 Million SEK | 17.6% |
| 2019 Q3 | -27.74 Million SEK | 15.68% |
| 2019 Q1 | -22.79 Million SEK | 17.53% |
| 2018 Q2 | -24.55 Million SEK | -109.87% |
| 2018 Q3 | -30.81 Million SEK | -25.52% |
| 2018 Q4 | -27.64 Million SEK | 10.3% |
| 2018 FY | -27.64 Million SEK | -64.0% |
| 2018 Q1 | -11.69 Million SEK | 30.6% |
| 2017 Q3 | -22.5 Million SEK | -96.8% |
| 2017 Q2 | -11.43 Million SEK | 29.22% |
| 2017 Q1 | -16.15 Million SEK | -36.18% |
| 2017 Q4 | -16.85 Million SEK | 25.1% |
| 2017 FY | -16.85 Million SEK | -42.08% |
| 2016 FY | -11.86 Million SEK | -143.73% |
| 2016 Q4 | -11.86 Million SEK | 28.57% |
| 2016 Q3 | -16.61 Million SEK | 21.03% |
| 2016 Q2 | -21.03 Million SEK | -1441.47% |
| 2016 Q1 | -1.36 Million SEK | 71.97% |
| 2015 Q4 | -4.86 Million SEK | 37.06% |
| 2015 Q1 | 1.64 Million SEK | -78.55% |
| 2015 Q3 | -7.73 Million SEK | 22.35% |
| 2015 Q2 | -9.95 Million SEK | -705.52% |
| 2015 FY | -4.86 Million SEK | -163.48% |
| 2014 FY | 7.66 Million SEK | 223.77% |
| 2014 Q4 | 7.66 Million SEK | 0.0% |
| 2013 FY | 2.36 Million SEK | 201.24% |
| 2012 FY | -2.33 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alzinova AB (publ) | -21.22 Million SEK | 19.853% |
| Amniotics AB (publ) | -5.63 Million SEK | -202.06% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | -687.228% |
| BioArctic AB (publ) | -606.58 Million SEK | 97.195% |
| Calliditas Therapeutics AB (publ) | 5.4 Million SEK | 415.037% |
| Genovis AB (publ.) | -43.94 Million SEK | 61.284% |
| LIDDS AB (publ) | -13.51 Million SEK | -25.903% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 131.964% |
| OncoZenge AB (publ) | -12.62 Million SEK | -34.727% |
| Saniona AB (publ) | 40.44 Million SEK | 142.06% |
| Simris Alg AB (publ) | 85.07 Million SEK | 119.996% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 94.901% |
| AcouSort AB (publ) | -23.98 Million SEK | 29.075% |
| Active Biotech AB (publ) | -33.2 Million SEK | 48.759% |
| Camurus AB (publ) | -1.16 Billion SEK | 98.54% |
| Cantargia AB (publ) | -139.74 Million SEK | 87.827% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | -1743.12% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 79.685% |
| Mendus AB (publ) | -96.29 Million SEK | 82.333% |
| Kancera AB (publ) | -45.69 Million SEK | 62.768% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 79.305% |
| Lipum AB (publ) | -8.46 Million SEK | -100.969% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 46.716% |
| NextCell Pharma AB | -46.79 Million SEK | 63.642% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 110.243% |
| Xintela AB (publ) | -7.8 Million SEK | -117.851% |
| Ziccum AB (publ) | -2.13 Million SEK | -696.069% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 42.103% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 10.745% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 87.686% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 86.863% |
| CombiGene AB (publ) | -101.44 Million SEK | 83.229% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 79.275% |
| Intervacc AB (publ) | -88.16 Million SEK | 80.703% |
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 65.99% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 65.931% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 182.945% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 79.685% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 56.803% |
| Aptahem AB (publ) | 2.9 Million SEK | 684.878% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 94.83% |
| Fluicell AB (publ) | -2.76 Million SEK | -515.708% |
| Biovica International AB (publ) | -58.73 Million SEK | 71.037% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 62.377% |
| Abliva AB (publ) | -57.24 Million SEK | 70.28% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 91.262% |
| 2cureX AB (publ) | -13.4 Million SEK | -26.927% |
| I-Tech AB | -83.26 Million SEK | 79.568% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 112.629% |
| Cyxone AB (publ) | -16.67 Million SEK | -2.052% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 69.559% |
| Biosergen AB | -1.88 Million SEK | -803.452% |
| Nanologica AB (publ) | -9.38 Million SEK | -81.21% |
| SynAct Pharma AB | -61.75 Million SEK | 72.454% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 20.56% |
| BioInvent International AB (publ) | -236.3 Million SEK | 92.801% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | -28.595% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 74.579% |
| Pila Pharma AB (publ) | -5.18 Million SEK | -228.359% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 18.184% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | -472.409% |